Intracranial dissemination of a macroprolactinoma

J. Assies; N. P.L.G. Verhoeff; D. A. Bosch; L. J. Hofland

doi:10.1111/j.1365-2265.1993.tb00351.x

Intracranial dissemination of a macroprolactinoma

J. Assies^*, N. P.L.G. Verhoeff, D. A. Bosch, L. J. Hofland

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

Abstract

A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. ¹²³I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with ¹¹¹In-SMS, somatostatin treatment was added to the CV 205-502.

Original language	English
Pages (from-to)	539-546
Number of pages	8
Journal	Clinical Endocrinology
Volume	38
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2265.1993.tb00351.x
Publication status	Published - May 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2265.1993.tb00351.x

Cite this

@article{d4548422218841cca0ee3c8ca5629bb4,

title = "Intracranial dissemination of a macroprolactinoma",

abstract = "A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502.",

author = "J. Assies and Verhoeff, {N. P.L.G.} and Bosch, {D. A.} and Hofland, {L. J.}",

year = "1993",

month = may,

doi = "10.1111/j.1365-2265.1993.tb00351.x",

language = "English",

volume = "38",

pages = "539--546",

journal = "Clinical Endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Intracranial dissemination of a macroprolactinoma

AU - Assies, J.

AU - Verhoeff, N. P.L.G.

AU - Bosch, D. A.

AU - Hofland, L. J.

PY - 1993/5

Y1 - 1993/5

N2 - A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502.

AB - A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502.

UR - http://www.scopus.com/inward/record.url?scp=0027285697&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.1993.tb00351.x

DO - 10.1111/j.1365-2265.1993.tb00351.x

M3 - Article

C2 - 8101148

AN - SCOPUS:0027285697

SN - 0300-0664

VL - 38

SP - 539

EP - 546

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 5

ER -

Intracranial dissemination of a macroprolactinoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this